| Drug Name |
Ribociclib |
| Drug ID |
BADD_D02483 |
| Description |
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. |
| Indications and Usage |
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EF02 |
| DrugBank ID |
DB11730
|
| KEGG ID |
D10883
|
| MeSH ID |
C000589651
|
| PubChem ID |
44631912
|
| TTD Drug ID |
D08MXP
|
| NDC Product Code |
0078-0860; 0078-0874; 0078-0867 |
| UNII |
TK8ERE8P56
|
| Synonyms |
ribociclib | LEE011 | Kisqali |
